These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235 [No Abstract] [Full Text] [Related]
3. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247 [TBL] [Abstract][Full Text] [Related]
4. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer. Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586 [TBL] [Abstract][Full Text] [Related]
5. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749 [TBL] [Abstract][Full Text] [Related]
6. Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images. Sager S; Kabasakal L; Ocak M; Maecke H; Uslu L; Halaç M; Asa S; Sager G; Önsel Ç; Kanmaz B Nucl Med Commun; 2013 Dec; 34(12):1190-5. PubMed ID: 24121313 [TBL] [Abstract][Full Text] [Related]
7. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617 [TBL] [Abstract][Full Text] [Related]
8. Role of Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903 [TBL] [Abstract][Full Text] [Related]
9. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER. Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863 [TBL] [Abstract][Full Text] [Related]
10. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628 [TBL] [Abstract][Full Text] [Related]
11. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241 [TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL; Xue YL; Song HJ; Luo QY Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer. Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma. Rodríguez-Bel L; Sabaté-Llobera A; Rossi-Seoane S; Reynés-Llompart G; Vercher Conejero JL; Cos-Domingo M; Moreno-Llorente P; Pérez-Maraver M; Cortés-Romera M; Gámez Cenzano C Clin Nucl Med; 2019 Mar; 44(3):194-200. PubMed ID: 30562193 [TBL] [Abstract][Full Text] [Related]
16. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
17. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877 [TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Mucha SA; Kunert-Radek J; Pomorski L Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852 [TBL] [Abstract][Full Text] [Related]